CL2017002745A1 - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Info

Publication number
CL2017002745A1
CL2017002745A1 CL2017002745A CL2017002745A CL2017002745A1 CL 2017002745 A1 CL2017002745 A1 CL 2017002745A1 CL 2017002745 A CL2017002745 A CL 2017002745A CL 2017002745 A CL2017002745 A CL 2017002745A CL 2017002745 A1 CL2017002745 A1 CL 2017002745A1
Authority
CL
Chile
Prior art keywords
sulfonimidoylpurinone
prophylaxis
derivatives
treatment
viral infections
Prior art date
Application number
CL2017002745A
Other languages
English (en)
Inventor
Hongying Yun
Xiufang Zheng
Chungen Liang
Kun Miao
Jianping Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002745(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017002745A1 publication Critical patent/CL2017002745A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención se refiere a compuestos de fórmula (I), en la que R 1 , R 2 y R 3 son como se han descrito en el presente documento, y sus profármacos o sales, enantiómeros o diastereómeros farmacéuticamente aceptables de los mismos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.</p>
CL2017002745A 2015-05-08 2017-10-30 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas CL2017002745A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08

Publications (1)

Publication Number Publication Date
CL2017002745A1 true CL2017002745A1 (es) 2018-05-18

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002745A CL2017002745A1 (es) 2015-05-08 2017-10-30 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Country Status (32)

Country Link
US (3) US9708325B2 (es)
EP (1) EP3294740B1 (es)
JP (1) JP6738352B2 (es)
KR (1) KR102690131B1 (es)
CN (1) CN107580596B (es)
AR (1) AR104528A1 (es)
AU (3) AU2016260683B2 (es)
BR (1) BR112017023959B1 (es)
CA (1) CA2982704C (es)
CL (1) CL2017002745A1 (es)
CO (1) CO2017009994A2 (es)
CR (1) CR20170496A (es)
DK (1) DK3294740T3 (es)
ES (1) ES2753777T3 (es)
HR (1) HRP20191942T1 (es)
HU (1) HUE045906T2 (es)
IL (2) IL254947B (es)
LT (1) LT3294740T (es)
MX (2) MX376761B (es)
MY (1) MY182353A (es)
NZ (2) NZ775222A (es)
PE (1) PE20171620A1 (es)
PH (1) PH12017502009A1 (es)
PL (1) PL3294740T3 (es)
PT (1) PT3294740T (es)
RS (1) RS59435B1 (es)
RU (1) RU2745269C2 (es)
SG (1) SG10202108841YA (es)
SI (1) SI3294740T1 (es)
TW (2) TWI706954B (es)
UA (1) UA120450C2 (es)
WO (1) WO2016180695A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
RU2751349C2 (ru) 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции
CA3034185A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
WO2019155042A1 (en) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
PE20211456A1 (es) * 2018-02-28 2021-08-05 Hoffmann La Roche Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
US12503461B2 (en) 2019-09-20 2025-12-23 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
JP7684316B2 (ja) * 2020-01-27 2025-05-27 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
WO2021154662A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2025522978A (ja) 2022-07-14 2025-07-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの処置のためのホスホリルプリノン化合物
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EA200702235A1 (ru) * 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
DK2776439T3 (en) 2011-11-09 2018-10-22 Janssen Sciences Ireland Uc PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
WO2014154859A1 (en) 2013-03-29 2014-10-02 Janssen R&D Ireland Macrocyclic deaza-purinones for the treatment of viral infections
CN112898308B (zh) 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
RU2751349C2 (ru) * 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции

Also Published As

Publication number Publication date
EP3294740B1 (en) 2019-09-04
US20160326177A1 (en) 2016-11-10
HK1247925A1 (zh) 2018-10-05
PH12017502009A1 (en) 2018-03-26
TWI706954B (zh) 2020-10-11
AU2020256348B2 (en) 2022-06-16
HRP20191942T1 (hr) 2020-01-10
CR20170496A (es) 2017-12-05
RU2017142577A3 (es) 2019-10-31
CA2982704C (en) 2023-10-24
KR20180003612A (ko) 2018-01-09
BR112017023959B1 (pt) 2023-05-02
CN107580596A (zh) 2018-01-12
BR112017023959A2 (pt) 2018-07-17
NZ735648A (en) 2023-06-30
CO2017009994A2 (es) 2018-02-20
KR102690131B1 (ko) 2024-07-31
IL254947A0 (en) 2017-12-31
CN107580596B (zh) 2020-07-14
CA2982704A1 (en) 2016-11-17
EP3294740A1 (en) 2018-03-21
IL254947B (en) 2021-02-28
AU2020256348A1 (en) 2020-11-12
MX393198B (es) 2025-03-19
MX2017014033A (es) 2018-03-01
IL280769A (en) 2021-04-29
US20170275286A1 (en) 2017-09-28
SI3294740T1 (sl) 2019-12-31
MX376761B (es) 2025-03-07
US20200109144A1 (en) 2020-04-09
AU2022204666A1 (en) 2022-07-21
AR104528A1 (es) 2017-07-26
JP6738352B2 (ja) 2020-08-12
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
AU2016260683B2 (en) 2020-10-29
TWI768467B (zh) 2022-06-21
UA120450C2 (uk) 2019-12-10
MY182353A (en) 2021-01-20
IL280769B1 (en) 2023-03-01
ES2753777T3 (es) 2020-04-14
RU2017142577A (ru) 2019-06-10
US10399983B2 (en) 2019-09-03
MX2020010949A (es) 2022-06-16
TW201716410A (zh) 2017-05-16
LT3294740T (lt) 2019-11-25
IL280769B2 (en) 2023-07-01
WO2016180695A1 (en) 2016-11-17
PE20171620A1 (es) 2017-11-02
HUE045906T2 (hu) 2020-01-28
PT3294740T (pt) 2019-10-29
US11242345B2 (en) 2022-02-08
RS59435B1 (sr) 2019-11-29
JP2018515509A (ja) 2018-06-14
PL3294740T3 (pl) 2020-03-31
AU2016260683A1 (en) 2017-10-12
NZ775222A (en) 2024-09-27
SG10202108841YA (en) 2021-09-29
DK3294740T3 (da) 2019-11-04
US9708325B2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MX2023001876A (es) Derivados de rapamicina.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
UY40872A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
CO2018004213A2 (es) Compuesto piranodipiridínico
PY1515461A (es) Derivados de Dihidropirrolopirimidina
MX2017003788A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
GT201600232A (es) Derivados de diheterociclo enlazado a cicloalquilo
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
NI201600171A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1